Business Context and Reporting Period
Company: Axcelis Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 30, 2009
Event: Completion of the sale of all common shares in SEN Corporation (a joint venture with Sumitomo Heavy Industries, Ltd.) to Sumitomo Heavy Industries, Ltd. (SHI).
Key Financial Metrics
- Transaction Proceeds: The Company received 13 Billion Yen in cash, resulting in net proceeds of approximately $122.3 million after advisor fees and expenses.
- Debt Reduction: A portion of the proceeds was used to pay off, in full, the amounts due on the Company's 4.25% Convertible Senior Subordinated Notes.
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, or operating cash flow figures for the reporting period; it focuses on the transaction mechanics.
Material Changes
- Asset Disposition: Axcelis exited its equity interest in SEN Corporation, transferring ownership to SHI.
- Agreement Termination: The Organization Agreement (dated Dec 3, 1982) and Master License Agreement (dated Jan 16, 1996) between Eaton Corporation (predecessor) and SHI/SEN were terminated.
- Intellectual Property: A new cross-license agreement was executed granting non-exclusive, perpetual, royalty-free worldwide rights to certain patents and technical information shared prior to the transaction date.
Outlook, Risks, and Unusual Items
- Licensing Restrictions: The new license agreement excludes technical information related to the Optima HD and Optima XE products, as well as patents related to molecular implant work and certain Optima HD/XE patents.
- Warranties: Neither party provides support for the other's use of licensed IP, and warranties regarding validity or freedom from infringement are disclaimed.
- Pro Forma Data: Pro forma financial information is filed as Exhibit 99.2 but is not detailed within the text of this summary.
Investor Verification Checklist
- Verify the exact amount of debt retired from the 4.25% Convertible Senior Subordinated Notes using the $122.3 million net proceeds.
- Review Exhibit 99.2 for pro forma financial impact on the Company's balance sheet and liquidity.
- Confirm the specific scope of excluded patents (Optima HD, Optima XE, molecular implant) in the License Agreement (Exhibit 10.1) to assess future competitive positioning.
- Check subsequent filings for the impact of this transaction on future revenue streams previously derived from SEN Corporation.